The All of Us precision medicine research platform comprises nearly 350,000 participant partners across the U.S. The agency’s goal is to enroll 1 million participants in the study to provide a large, diverse data pool to support studies on health, disease and precision medicine therapies.
Under the new All of Us research initiatives for COVID-19, the program will test blood samples from 10,000 or more participants who recently joined for COVID-19 antibodies. Working with the Frederick National Laboratory for Cancer Research, the CDC and Quest Diagnostics, among others, the testing will show the prevalence of COVID-19 among All of Us participants and help researchers identify the spread of the disease across regions and communities.
All of Us has also launched a new online survey to assess participants’ physical and mental health during the pandemic. Participants are asked to take the survey once per month and are asked about COVID-19 symptoms, stress, social distancing and economic impacts.
The program is also collecting information from participants’ EHRs to help researchers look for patterns and learn more about COVID-19 symptoms and associated health problems. More than 200,000 participants have shared their EHRs as of June 16.
More articles on data analytics:
Cleveland Clinic develops risk calculator to predict COVID-19 test results: 5 details
How NYC Health + Hospitals combined data streams, clinical expertise for ‘epidemic intelligence’ efforts
Cleveland Clinic receives $7.2M NIH grant to study MS diagnostics
